ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 875

Pericardial Involvement in Biopsy-Proven Giant-Cell Arteritis (GCA) Patients Detected By CT Angiography (CTA): Prevalence at Diagnosis and Outcome with Glucocorticoid (GC) Treatment

Javier Marco-Hernández1, Sergio Prieto-González2, Rosa Gilabert3, Pedro Arguis4, Georgina Espígol-Frigolé5, Ana García-Martínez6, Ester Planas-Rigol5, Marc Corbera-Bellalta2, Nekane Terrades-Garcia2, Jose Hernández-Rodríguez2 and Maria C. Cid7, 1Internal Medicine, Hospital Clínic, Barcelona, Spain, 2Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 3Center for Diagnostic Imaging, Hospital Clínic, Barcelona, Spain, 4Center for Diagnostic Imaging, Hospital Clínic. IDIBAPS. University of Barcelona, Barcelona, Spain, 5Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 6Emergeny Department, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 7Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: giant cell arteritis and vasculitis, Imaging

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In GCA, cranial artery involvement is particularly frequent and underlies the classical manifestations and complications of the disease. Symptomatic pericarditis has been occasionally described as part of the presenting symptoms. However, the frequency of imaging-detected pericardial involvement has not been systematically evaluated. The aim of our study was to assess the prevalence of pericardial involvement detected by CTA in patients with newly diagnosed GCA, as well as the potential relationship with pericardial symptoms, GCA manifestations, laboratory data, or the presence of large-vessel vasculitis (LVV). The outcome of pericardial involvement with GC treatment was also analyzed.

Methods: From July 2007 to January 2015, 63 patients diagnosed with biopsy-proven GCA at our institution were subjected to CTA according to a defined protocol as part of a prospective study assessing LVV [Prieto-González S et al; Ann Rheum Dis 2012]. These patients were treatment-naïve or had received GC for ≤ 3 days. A follow-up CTA was scheduled to evaluate the outcome of imaging-detected lesions with GC treatment. Post-hoc assessment of CTA images was performed in order to detect pericardial abnormalities including pericardial thickening (thickness of the pericardial membrane of at least 4mm) and/or pericardial effusion (presence of liquid between the pericardial membrane and the heart). Specific GCA symptoms and laboratory features, as well as classical pericardial manifestation were recorded.

Results: Among the 63 patients included, 45 were women and 18 men, aged 78 years (range 56-92). At the time of GCA diagnosis, pericardial involvement was present in 18 patients (29%), consisting of thickening (4-7mm) in 8 patients (13%) and effusion (4-18mm) in 10 (16%). Forty-six patients completed the follow-up CTA assessment after a median follow-up of 16 months (range 12-135). At the second imaging, 8 of them (17%) still had pericardial involvement: thickening in 5 (11%) and effusion in 3 (6%). All patients were asymptomatic regarding classical pericarditis symptoms. No relationship was observed between the presence of pericardial involvement and GCA manifestations, laboratory data or the detection of LVV.

Conclusion:  In our series, about one third of patients with newly diagnosed GCA have pericardial involvement, consisting of a subclinical mild to moderate pericardial thickening or effusion that improves during the follow-up with GC treatment. Supported by SAF14/57708-R.


Disclosure: J. Marco-Hernández, None; S. Prieto-González, None; R. Gilabert, None; P. Arguis, None; G. Espígol-Frigolé, None; A. García-Martínez, None; E. Planas-Rigol, None; M. Corbera-Bellalta, None; N. Terrades-Garcia, None; J. Hernández-Rodríguez, None; M. C. Cid, None.

To cite this abstract in AMA style:

Marco-Hernández J, Prieto-González S, Gilabert R, Arguis P, Espígol-Frigolé G, García-Martínez A, Planas-Rigol E, Corbera-Bellalta M, Terrades-Garcia N, Hernández-Rodríguez J, Cid MC. Pericardial Involvement in Biopsy-Proven Giant-Cell Arteritis (GCA) Patients Detected By CT Angiography (CTA): Prevalence at Diagnosis and Outcome with Glucocorticoid (GC) Treatment [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/pericardial-involvement-in-biopsy-proven-giant-cell-arteritis-gca-patients-detected-by-ct-angiography-cta-prevalence-at-diagnosis-and-outcome-with-glucocorticoid-gc-treatment/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pericardial-involvement-in-biopsy-proven-giant-cell-arteritis-gca-patients-detected-by-ct-angiography-cta-prevalence-at-diagnosis-and-outcome-with-glucocorticoid-gc-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology